CFI-400945

Phase 2Small molecule

TTreadwell Therapeutics, Inc

CFI-400945 is one of 51 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Voltaren

Novartis

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

CFI-400945

TTreadwell Therapeutics, Inc

Phase 2

2 9

Zinecard

CChildren's Oncology Group

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Breast Cancer

NCT03624543

Phase 2Active, not recruiting

Breast Cancer

NCT04176848

Clinical

Trials by Indication[1]

Breast Cancer2 trials

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03624543·51 enrolled

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT04176848·15 enrolled

Advanced Cancer1 trial

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

Completed·UUniversity Health Network, Toronto·Phase 1·NCT01954316·46 enrolled

Prostate Cancer1 trial

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03385655·200 enrolled

CMML1 trial

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Active, not recruiting·TTreadwell Therapeutics, Inc·Phase 1/2·NCT04730258·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CFI-400945. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CFI-400945 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CFI-400945. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Treadwell Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTreadwell Therapeutics, Inc

CFI-400945

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer2 trials

Advanced Cancer1 trial

Prostate Cancer1 trial

CMML1 trial

References

Drug Info

Quick Facts

Related News